Novartis Announced Its Intention To Separate Sandoz, Its Generics And Biosimilars Division Into A New Publicly Traded Standalone Company, By Way Of A 100% Spin-Off.The Spin-Off Aims To Maximize Shareholder Value By Creating The #1 European Generics Company And A Global Leader In Biosimilars, Allowing Novartis Shareholders To Participate Fully In The Potential Future Upside For Both Sandoz And Novartis Innovative Medicines.For Both The Innovative Medicines And Sandoz Businesses, The Spin-Off Would Enable Enhanced Focus And The Ability To Pursue Independent Growth Strategies. Sandoz Is Expected To Deliver Its Next Wave Of Growth Based On The Existing Biosimilars Pipeline Of 15+ Molecules, A Strong And Experienced Management Team And Organization. Novartis Aims To Become A Focused Innovative Medicines Company With A Stronger Financial Profile, And Improved Return On Capital.The Standalone Sandoz Would Be Headquartered In Switzerland And Listed On The Six Swiss Exchange, With An American Depositary Receipt (Adr) Program In The Us.Joerg Reinhardt, Chair Of The Board Of Directors Of Novartis, Said:
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!